rapamycin → SREBP1 — Novel Hypothesis | InTree.AI

Novel Hypothesis

rapamycinSREBP1

Rapamycin reduces mTORC1-mediated SREBP1c activation, limiting de novo lipogenesis and cancer cell membrane biosynthesis.

Convergence: 79%3 bridgesoncology

Bridge Entities

SREBP1cA→B quality: 0.70B→C quality: 0.70

rapamycin PARTICIPATES IN SREBP1c, which CONNECTED TO SREBP1

A→B Evidence (11 total)

“Reprogramming SREBP1-dependent lipogenesis and inflammation in high-risk breast with licochalcone A: a novel path to cancer prevention.”— Reprogramming SREBP1-dependent lipogenesis and inflammation in high-risk breast with licochalcone A: a novel path to cancer prevention. (2024)DOI

“Brexpiprazole suppresses cell proliferation and de novo lipogenesis through AMPK/SREBP1 pathway in colorectal cancer.”— Brexpiprazole suppresses cell proliferation and de novo lipogenesis through AMPK/SREBP1 pathway in colorectal cancer. (2023)DOI

AB23AA→B quality: 0.50B→C quality: 0.50

rapamycin CO MENTIONED WITH AB23A, which CO MENTIONED WITH SREBP1

FASNA→B quality: 0.50B→C quality: 0.50

rapamycin CO MENTIONED WITH FASN, which CO MENTIONED WITH SREBP1

Why This Is Novel

The rapamycin–SREBP1 connection is partially studied (50 co-occurrences), but the SREBP1c-mediated mechanism may represent a less-explored angle within this relationship.

Discovered by InTree.AI — analyzing 250M+ scientific papers